Curis, Inc. (CRIS) reported a notable shift in its financial landscape, posting a net income of $19.4 million for Q4 2025, primarily due to a one-time non-cash gain from the sale of Erivedge. However, the company anticipates no meaningful revenue moving forward, as royalties from Erivedge ceased in November 2025. This transition underscores Curis’s strategic pivot away from legacy revenue streams and reliance on recent PIPE financing to sustain operations into 2027.
The focus now shifts to the company’s clinical pipeline, particularly the TakeAim Lymphoma (PCNSL) and TakeAim CLL studies. Management has confirmed that resources will be prioritized for PCNSL registration, while initial CLL data is expected to be presented at the ASH Annual Meeting in December. Early results from the AML triplet study show promise, with several patients achieving measurable residual disease (MRD) conversion.
For market professionals, Curis’s operational pivot highlights the importance of monitoring clinical trial progress and funding strategies in biotech. The full details of this strategic shift and its implications can be explored further in the original article.
Source: fool.com